The effect of continuous HRT on glucose homeostasis and plasma lipids. A placebo-controlled study in postmenopausal women with type 2 diab
(2006) In Maturitas 53(4). p.430-438- Abstract
- Background
Hyperandrogenicity in women is a risk factor for cardiovascular disease and noninsulin-dependent diabetes mellitus (NIDDM). Estradiol alone decreases hyperandrogenicity and have beneficial effects on glucose metabolism and plasma lipids in postmenopausal women with type 2 diabetes.
Objectives
To analyse effects on glucose homeostasis and plasma lipids by 2 mg estradiol and 1 mg norethisterone acetate (NETA) given as a daily tablet during 6 months in postmenopausal women with type 2 diabetes.
Design
Randomised, double-blind, placebo-controlled, cross-over design.
Material and methods
Thirty-one postmenopausal women with type 2... (More) - Background
Hyperandrogenicity in women is a risk factor for cardiovascular disease and noninsulin-dependent diabetes mellitus (NIDDM). Estradiol alone decreases hyperandrogenicity and have beneficial effects on glucose metabolism and plasma lipids in postmenopausal women with type 2 diabetes.
Objectives
To analyse effects on glucose homeostasis and plasma lipids by 2 mg estradiol and 1 mg norethisterone acetate (NETA) given as a daily tablet during 6 months in postmenopausal women with type 2 diabetes.
Design
Randomised, double-blind, placebo-controlled, cross-over design.
Material and methods
Thirty-one postmenopausal women with type 2 diabetes, glycosylated haemoglobin (HbA1c) of 6% or more and sex hormone-binding globulin (SHBG) values of 60 nmol/L or less were included. Anthropometric variables, blood pressure, sex steroid hormones, HbA1c, serum and lipoprotein lipids, plasminogen activator inhibitor 1 (PAI-1) and insulin-like growth factor 1 (IGF-1) were measured. An oral glucose tolerance test (OGTT) was performed and blood glucose, insulin and C-peptide were analysed. All measurements were taken at baseline and after each 6-month period.
Results
An increase of SHBG and a decrease in free testosterone and PAI-1 levels was induced by the estradiol/NETA treatment compared with placebo. Lipoprotein(a) decreased but otherwise lipid metabolism was unaffected. No differences were recorded in glucose homeostasis between active treatment and placebo.
Conclusion
Estradiol/NETA therapy decreased hyperandrogenicity in postmenopausal women with type 2 diabetes. Lipoprotein(a) and PAI-1 which are independent risk factors for coronary heart disease decreased. No changes in glucose homeostasis were found. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1136188
- author
- Thunell, Louise LU ; Adersson, B ; Glassell, M and Mattsson, L-A
- organization
- publishing date
- 2006
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Hormone replacement therapy, Type 2 diabetes, Glucose homeostasis, Lipids, Postmenopausal women, PAI-1
- in
- Maturitas
- volume
- 53
- issue
- 4
- pages
- 430 - 438
- publisher
- Elsevier
- external identifiers
-
- scopus:33644635448
- ISSN
- 1873-4111
- DOI
- 10.1016/j.maturitas.2005.07.008
- language
- English
- LU publication?
- yes
- id
- 2e6d5538-1490-4dcb-9c4f-2d15f136fc0e (old id 1136188)
- date added to LUP
- 2016-04-01 12:17:29
- date last changed
- 2022-01-27 01:34:06
@article{2e6d5538-1490-4dcb-9c4f-2d15f136fc0e,
abstract = {{Background<br/><br>
<br/><br>
Hyperandrogenicity in women is a risk factor for cardiovascular disease and noninsulin-dependent diabetes mellitus (NIDDM). Estradiol alone decreases hyperandrogenicity and have beneficial effects on glucose metabolism and plasma lipids in postmenopausal women with type 2 diabetes.<br/><br>
Objectives<br/><br>
<br/><br>
To analyse effects on glucose homeostasis and plasma lipids by 2 mg estradiol and 1 mg norethisterone acetate (NETA) given as a daily tablet during 6 months in postmenopausal women with type 2 diabetes.<br/><br>
Design<br/><br>
<br/><br>
Randomised, double-blind, placebo-controlled, cross-over design.<br/><br>
Material and methods<br/><br>
<br/><br>
Thirty-one postmenopausal women with type 2 diabetes, glycosylated haemoglobin (HbA1c) of 6% or more and sex hormone-binding globulin (SHBG) values of 60 nmol/L or less were included. Anthropometric variables, blood pressure, sex steroid hormones, HbA1c, serum and lipoprotein lipids, plasminogen activator inhibitor 1 (PAI-1) and insulin-like growth factor 1 (IGF-1) were measured. An oral glucose tolerance test (OGTT) was performed and blood glucose, insulin and C-peptide were analysed. All measurements were taken at baseline and after each 6-month period.<br/><br>
Results<br/><br>
<br/><br>
An increase of SHBG and a decrease in free testosterone and PAI-1 levels was induced by the estradiol/NETA treatment compared with placebo. Lipoprotein(a) decreased but otherwise lipid metabolism was unaffected. No differences were recorded in glucose homeostasis between active treatment and placebo.<br/><br>
Conclusion<br/><br>
<br/><br>
Estradiol/NETA therapy decreased hyperandrogenicity in postmenopausal women with type 2 diabetes. Lipoprotein(a) and PAI-1 which are independent risk factors for coronary heart disease decreased. No changes in glucose homeostasis were found.}},
author = {{Thunell, Louise and Adersson, B and Glassell, M and Mattsson, L-A}},
issn = {{1873-4111}},
keywords = {{Hormone replacement therapy; Type 2 diabetes; Glucose homeostasis; Lipids; Postmenopausal women; PAI-1}},
language = {{eng}},
number = {{4}},
pages = {{430--438}},
publisher = {{Elsevier}},
series = {{Maturitas}},
title = {{The effect of continuous HRT on glucose homeostasis and plasma lipids. A placebo-controlled study in postmenopausal women with type 2 diab}},
url = {{http://dx.doi.org/10.1016/j.maturitas.2005.07.008}},
doi = {{10.1016/j.maturitas.2005.07.008}},
volume = {{53}},
year = {{2006}},
}